46 results about "Mesangial cell" patented technology

Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like. A polyion complex in the form of a non-polymeric micelle consisting of a double-stranded ribonucleic acid and a block copolymer represented by the formula (I) or (II) below, which are electrostatically bound together, wherein the polyion complex has an average particle diameter of less than 100 nm as measured by a dynamic light scattering measuring method:wherein each symbol is as defined in the specification.

The invention discloses and claims benzimidazole compounds of formula (I): wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and / or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.

A novel cell seeded hollow fiber bioreactor is described as a potential bioartificial kidney. Endothelial cells along with pericyte, vascular smooth muscle, and / or mesangial cells or any mesenchymally derived support cells are seeded along a hollow fiber in a perfused bioreactor to reproduce the ultrafiltration function and transport function of the kidney. Maintenance of tissue specific function and ultrastructure suggest that this bioreactor provides an economical device for treating renal failure.

The invention discloses and claims benzimidazole compounds of formula (I):wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitotic agents.

The invention provides a glomerulus-targeted protein nanoparticle pharmaceutical composition and an application thereof. The protein nanoparticle pharmaceutical composition is mainly prepared from a protein ingredient, a pharmacological active substance and a stabilizer, and the grain size of the protein nanoparticle pharmaceutical composition ranges from 10nm to 170nm. With the application of the pharmaceutical composition, passive targeted drug delivery of glomerular mesangial cells is achieved, and the aggregation concentration of a drug in a glomerulus is obviously improved or the aggregation duration of the drug in the glomerulus is prolonged, so that the curative effect of the drug is remarkably improved, and meanwhile, the toxic and side effects of the drug on a non-targeted part are greatly reduced.

The invention provides seven spiro heterocyclic terpenoid compounds which adopt novel structures and are obtained from ganoderma lucidum as well as pharmaceutical composition, preparation methods and applications thereof to preparation of drugs for treating diabetic nephropathy or chronic nephropathy or health-care food. The compounds have significant effect on inhibition of production of active oxygen by high-glucose-induced rat mesangial cell strains, and oxidative stress commonly exists in the chronic nephropathy, so that application prospects of the compounds in the drugs for the chronic nephropathy are prompted.

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

The invention belongs to the field of biological recognition, and discloses a cell detection method, device and apparatus for a glomerular pathological section image, and the method comprises the steps: obtaining a to-be-detected glomerular pathological section image; inputting the to-be-detected glomerular pathological section image into a preset neural network model for identification and detection, with the preset neural network model being obtained by training a neural network through a predetermined number of glomerular pathological section images for identifying and labeling mesangial cells, endothelial cells and podocytes; respectively outputting probability graphs of mesangial cells, endothelial cells and podocytes in the glomerular pathological section image to be detected from three output channels of a preset neural network model; and calculating the number of the mesangial cells, the endothelial cells and the podocytes in the glomerular pathological section image to be detected according to the probability graphs of the mesangial cells, the endothelial cells and the podocytes. The causes and conditions of the patient are determined according to the number of mesangial cells, endothelial cells and podocyte, and a treatment scheme is made accurately.

The invention discloses an application of Eucommia lignans in preparing medicaments for preventing and treating hypertension-induced renal injury. The Eucommia lignans are extracted from Eucommia barks as raw materials and used to prepare medicaments for preventing and treating hypertension-induced renal injury. The Eucommia lignans can better improve the damage of the renal glomeruli and tubules due to spontaneous hypertension and have the pharmacological action of inhibiting the expression of type III collagen and the proliferation of mesangial cells, so as to effectively prevent and treat hypertension-induced renal injury.

Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like. A polyion complex in the form of a non-polymeric micelle consisting of a double-stranded ribonucleic acid and a block copolymer represented by the formula (I) or (II) below, which are electrostatically bound together, wherein the polyion complex has an average particle diameter of less than 100 nm as measured by a dynamic light scattering measuring method:wherein each symbol is as defined in the specification.

The invention discloses a mesangial cell image processing method, which comprises the following steps of: dividing an image to be identified into an R-channel image, a G-channel image and a B-channelimage, and extracting a mesangial region from the G-channel image to obtain a mesangial grey-scale map; extracting a cell nucleus region from the R channel image to obtain a cell nucleus grey-scale map; and performing hole filling on the mesangial grey-scale map to obtain a filled mesangial grey-scale map, and finally, performing image intersection processing on the cell nucleus grey-scale map andthe filled mesangial grey-scale map to obtain a mesangial cell region image. And a mesangial cell region image can be better positioned through different identification degrees in different channels.The invention further discloses a mesangial cell image processing device, related computer equipment and a storage medium.

The invention discloses an application of 5-pentyl-3-methoxy-phenol to preparation of products for preventing and treating oxidative stress or inflammatory response induced diseases. The chemical formula of 5-pentyl-3-methoxy-phenol is shown in the description. 5-pentyl-3-methoxy-phenol is an Nrf2 (nuclear factor-erythroid 2-related factor 2) signaling pathway agonist and an NF (nuclear factor)-kappa B signaling pathway inhibitor. 5-pentyl-3-methoxy-phenol can up-regulate the protein levels of Nrf2 as well as phase II detoxification enzyme NQO1 and antioxidant enzyme GCLM which are regulated by Nrf2, increase the level of glutathione as an endogenous antioxidant and inhibit generation of exogenous toxicant induced reactive oxygen species, and has a protective effect on exogenous toxicant induced oxidative damage to pulmonary bronchial epithelial cells, glomerular mesangial cells, human nerve cells and human breast cancer cells. 5-pentyl-3-methoxy-phenol can inhibit activation of an NF-kappa B signaling pathway, down-regulate inflammatory gene expression and inhibit LPS induced inflammatory response of macrophage RAW 264.7 of a mouse.

A gene expressed specifically in mesangial cells. A DNA expressed specifically in mesangial cells; a protein encoded by this DNA; an antibody binding to this protein, etc. These substances are indigenous to mesangial cells and, therefore, useful in, for example, identifying mesangial cells and detecting abnormalities in mesangial cells. Moreover, the above protein would be helpful for clarification of the functions of masangial cells and, in its turn, for clarification of the causes of diseases relating to masangial cells. This protein is expectedly applicable to the treatment and diagnosis of diseases relating to masangial cells.

When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

The invention discloses a cordyceps cicadae polysaccharide, a preparation method and application thereof in preparation of a medicament for preventing renal interstitial fibrosis. The method comprisesthe following steps: pulverizing cordyceps cicadae fruiting bodies, and performing sieving to obtain cordyceps cicadae fruiting body powder; ultrasonically extracting the fruiting body powder with distilled water, and then carrying out ultrahigh pressure treatment; preparing crude polysaccharide of the cordyceps cicadae fruiting body after the treatment; and then performing separation by using DEAE-cellulose anion column chromatography, and performing freeze-drying to obtain the purified polysaccharide. The method successfully prepares the cicada cordyceps polysaccharide treated and modifiedby ultrahigh pressure, and has the advantages of simple steps and higher efficiency. The intervention on a rat glomerular epithelial cell model shows that the polysaccharide can effectively inhibit the proliferation of rat glomerular epithelial cells (HMC), and has wide application prospect in the aspect of preventing renal interstitial fibrosis. The oxidation resistance of the cordyceps cicadae polysaccharide is obviously improved, and the cordyceps cicadae polysaccharide induces the apoptosis of high-glucose rat glomerular mesangial cells, has no toxicity to normal cells, and has good research value and commercial value.

The invention relates to application of sinomenine hydrochloride in promoting apoptosis of mesangial cells. Particularly, sinomenine hydrochloride can alleviate autophagy, proliferation and fibrosis of the mesangial cells caused by LPS. A combination of sinomenine hydrochloride and an autophagy inhibitor can promote the apoptosis of the mesangial cells. According to the application of sinomenine hydrochloride and the application of the combination of sinomenine hydrochloride and the autophagy inhibitor, a research basis is provided for combined treatment of kidney fibrosis disease through Chinese and Western medicine, and a good clinical application prospect is achieved.

This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.

When an anti-human BMP antibody was added to cells of an immortalized human mesangial cell line cultured in the presence of human BMP, the anti-human BMP antibody significantly suppressed the production of type IV collagen in mesangial cells. A number of signaling pathways are involved in abnormal proliferation of type IV collagen. It was therefore completely unpredictable whether merely blocking the BMP signal would indeed suppress the abnormal proliferation of type IV collagen. However, for the first time, the present inventors demonstrated that anti-BMP antibodies are very effective in suppressing the abnormal proliferation of type IV collagen. Thus, anti-BMP antibodies can be used as novel therapeutic agents for kidney diseases associated with abnormal proliferation of the mesangial matrix.

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R, R1, R2, R3, n, X1, X2, L1, and L2 are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

The invention discloses an application of oleanolic acid in pharmacy, and relates to the application of the oleanolic acid in the preparation of the medicine for restraining the activation of kidney fibroblast and mesangial cell, the medicine for deducing the kidney fibroblast, the medicine for improving the urine protein, the medicine for improving the kidney function, the medicine for reducing the kidney inflammation and the collagen deposition, and the medicine for reducing gene and protein related to the index of the kidney fibrosis. The invention designs a screening platform for the activation of the TGF (transforming growth factor)-beta 1-induced rat kidney fibroblast and mesangial cell, and discovers that the oleanolic acid with 4.56*10<-5>g / ml-4.56*10<-6>g / ml can restrain the activation of the TGF-beta 1-induced rat kidney fibroblast and mesangial cell. The invention further designs an in-vivo experiment of the oleanolic acid to UUO (unilateral ureteral obstruction) model rat and Platt model rat, and discovers that the oleanolic acid with the middle dose (6mg / kg / d) and the high dose (7mg / kg / d) can reduce the gene and the protein related to the urine protein, the kidney function and the kidney fibrosis of the UUO model rat and the Platt model rat.

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

The present invention provides a compound represented by the formula:wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.

The present invention provides the use of fucoidin in preparing a medicine for treating and / or preventing renal fibrosis disease. The embodiment of the invention proves that the fucoidin has the following functions: 1) reduces abnormal accumulation of extracellular matrix in renal glomerular mesangial region by reducing the protein expression level of FN and Col IV which are abnormally increasedin glomerular mesangial cells; and 2) obviously reduces the oxidative stress level of glomerular mesangial cells and the expression of inflammatory factors. Through the functions, the fucoidin can effectively reduce the renal function damage caused by renal fibrosis so as to achieve the effect of treating and / or preventing the renal fibrosis diseases, and therefore, the fucoidin can be developedas a potential medicament for treating and / or preventing the renal fibrosis diseases.

The invention discloses the application of 5-pentyl-3-methoxy-phenol in the preparation of oxidative stress or inflammatory response-induced disease prevention and treatment products. The chemical formula of the 5-pentyl-3-methoxy-phenol is: 5-pentyl-3-methoxy-phenol is an Nrf2 signaling pathway agonist and an NF-κB signaling pathway inhibitor. 5-Amyl-3-methoxy-phenol can up-regulate Nrf2 and its regulated phase II detoxification enzyme NQO1 and antioxidant enzyme GCLM protein levels, increase the level of endogenous antioxidant glutathione, and inhibit the induction of exogenous toxins The production of reactive oxygen species has a protective effect on the oxidative damage of pulmonary bronchial epithelial cells, mesangial cells, human nerve cells and human breast cancer cells induced by exogenous toxins. 5-pentyl-3-methoxy-phenol can inhibit the activation of NF-κB signaling pathway, down-regulate the expression of inflammatory genes, and has an inhibitory effect on LPS-induced inflammation in mouse macrophage RAW264.7 cells.

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.

This invention is directed to a compound of Formula Ior a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.